Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
Glenmark Pharmaceuticals is currently trading at Rs. 352.20, up by 1.55 points or 0.44% from its previous closing of Rs. 350.65 on the BSE.
The scrip opened at Rs. 352.00 and has touched a high and low of Rs. 354.30 and Rs. 348.60 respectively. So far 49336 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 706.90 on 31-Dec-2018 and a 52 week low of Rs. 267.30 on 14-Nov-2019.
Last one week high and low of the scrip stood at Rs. 359.25 and Rs. 336.40 respectively. The current market cap of the company is Rs. 9966.18 crore.
The promoters holding in the company stood at 46.58%, while Institutions and Non-Institutions held 38.80% and 14.62% respectively.
Glenmark Pharmaceuticals’ partner -- Seqirus Pty (Seqirus) has received marketing approval for Ryaltris from the Therapeutic Goods Administration (TGA), Australia. This paves the way for the launch of Ryaltris in Australia through Seqirus. Australia will be the first market globally where Ryaltris will be launched.
Under the terms of the agreement, Glenmark will be responsible for product supply and Seqirus will be responsible for regulatory filing and commercialization of the product in Australia. Glenmark is entitled to receive commercial milestone payments from Seqirus. Ryaltris will be manufactured at Glenmark’s Baddi manufacturing facility in Himachal Pradesh.
Earlier, Seqirus, part of Australia?based specialty biotechnology company CSL, had entered into an exclusive licensing agreement in July 2018 with Glenmark’s subsidiary Glenmark Specialty S.A. to commercialize Ryaltris in Australia.
Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1455.00 |
| Dr. Reddys Lab | 5730.85 |
| Cipla | 1459.75 |
| Zydus Lifesciences | 1007.20 |
| Lupin | 1564.60 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
